TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›SBC
SBC logo

SBC

SBC Medical Group Holdings Inc

Next earnings Aug 11, 2026 · consensus $0.12 EPS, $45.9M rev

Last earnings -7.7% on 2026-05-14

Hold
$3.25
▲ +3.17%
$3.25▼ -29.96%
over 1Y
L $2.87H $5.65
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.2%
1W+2.2%
1M+1.6%
3M-27.3%
YTD-24.9%
1Y-30.0%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
B
Valuation
Undervalued
Filings
Flagged
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy

Statistically dirt-cheap (6.5x P/E, ~half the market cap in cash) but a CEO-relative-controlled, related-party revenue base with unremediated control weaknesses caps trust.

P/E 6.5 · price / FY diluted EPS $0.50

The read

Middling fundamentals offset by an attractive price (~51% below fair value) — worth a look on the value angle.

On the numbers alone SBC screens as deep value: a 6.5x P/E, 1.9x sales, $164M cash against a $333M market cap (so an enterprise value near $210M for a business earning $51M), 73.3% gross margin, 38.9% operating margin and 20.5% ROE, with liabilities/equity of just 0.47x. Net income grew 9.4% to $51.0M even as revenue fell, and the asset-light franchise-management model needs almost no capital ($1.4M capex). If you take the financials at face value, the stock is priced for a business in decline while it is still highly profitable and over-capitalized.

But two things stop this from being a table-pounding buy. First, the trend is deteriorating, not stable: revenue dropped 15.5% to $174M after peaking at $205M in FY2024, and gross profit fell 18.4% — net income only rose because of below-the-line items (likely interest on the large cash pile and tax/mix), not core growth. More telling, operating cash flow was just $24.7M against $51.0M of reported net income — a wide gap that raises earnings-quality questions for a company whose 'profit' you are being asked to capitalize at face value.

Is SBC a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Covered call~60d expiry
  • Long 100 shares @ ~3.25
  • Short call 3.5 @ ~0.26 est
debit $299max +$51max −$298BE 2.99

HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY23FY24FY25
Revenue$194M$205M$174M
Gross profit$137M$156M$127M
Operating income$70.7M$70.3M$67.5M
Net income$39.4M$46.6M$51.0M
Diluted EPS$0.42$0.48$0.50
Net margin20.3%22.7%29.4%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$213M
EV / EBITDA3.0
EV / Sales1.2
EV / FCF9.1
P / FCF14.3
PEG (trailing)0.69
Earnings yield15.3%
FCF yield7.0%

Quality & risk

ROIC (est.)18.3%
Free cash flow$23.3M
Total debt$43.1M
Net cash$121M
Altman Z-Score4.17 safe
Piotroski F-Score4/9

Capital returns

Buyback yield1.5%
Dividend yield (est.)—
Shareholder yield1.5%
Shares Δ YoY-1.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. DEF 14A Proxy statement2026-05-28

    Annual-meeting proxy: director elections and pay votes

  2. 8-K Officer / director change2026-05-20

    Officer/director change disclosed amid ongoing governance remediation

  3. 8-K Earnings results2026-05-14

    Q1 FY26 (period Mar 31) quarterly report filed

  4. 10-Q Quarterly report2026-05-14

    Q1 FY26 (period Mar 31) quarterly report filed

  5. 10-K/A Restated periodic report2026-04-30

    Amended FY2025 10-K (Part III / corrections)

  6. 8-K Material agreement2026-04-23

    Entered a new material definitive agreement

  7. 8-K Earnings results2026-03-27

    FY2025 net income +9% to $51M, but revenue -16%; material weaknesses persist

  8. 10-K Annual report2026-03-27

    FY2025 net income +9% to $51M, but revenue -16%; material weaknesses persist

  9. 8-K Reg FD disclosure2026-01-05

    Furnished corporate/other-event update; no financial change

Recent filings

all on EDGAR ↗
ARSPeriod ending 2025-12-312026-05-28open ↗DEFA14AFiling2026-05-28open ↗DEF 14APeriod ending 2026-05-282026-05-28open ↗8-KPeriod ending 2026-05-142026-05-20open ↗PRE 14APeriod ending 2026-05-152026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗4Period ending 2026-04-282026-04-29open ↗4Period ending 2026-04-212026-04-23open ↗8-KPeriod ending 2026-04-192026-04-23open ↗SCHEDULE 13D/AFiling2026-04-21open ↗

Quality score

B
ValueGrowthProfitHealthMom.
ValueA
GrowthD
ProfitabilityA+
Financial healthA-
MomentumF
  • ✗Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✓Net margin above 10%
  • ✓Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✓P/E below 25

Fair value est.

$4.91

Undervalued +51% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.50 × (8.5 + 1.5 × 0.0% growth) × 1.16 quality = 9.8× multiple. An estimate, not a price target.

2.8752-week5.65
Revenue
$174M
-15.5% YoY
Net margin
29.4%
ROE
20.5%
P/E
6.5

SEC fundamentals · FY 2025

'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$174M-15.5%
Net income$51.0M+9.4%
Gross profit$127M-18.4%
Operating income$67.5M-4.0%
Diluted EPS$0.50+4.2%
Cash & equivalents$164M+31.0%
Total assets$380M+43.0%
Total liabilities$117M+64.8%
Stockholders' equity$248M+27.3%
Gross: 73.3%Op.: 38.9%L/E: 0.47x

Frequently asked

Is SBC Medical Group Holdings Inc (SBC) a buy?
SBC currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Statistically dirt-cheap (6.5x P/E, ~half the market cap in cash) but a CEO-relative-controlled, related-party revenue base with unremediated control weaknesses caps trust.
What is SBC's fair value?
A Modified-Graham model based on SBC's SEC fundamentals estimates a fair value of about $4.91. It is an estimate from reported earnings, not a price target.
Is SBC overvalued or undervalued?
Against a Modified-Graham fair-value estimate, SBC currently appears undervalued relative to its SEC-grounded earnings power.
What is SBC Medical Group Holdings Inc's quality score?
SBC scores 71.02810894141828/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001930313, latest 10-Q filed 2026-05-14) · EODHD · Proprietary analysis · as of 7/3/2026, 3:23:08 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 11:23 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 2 sales

2026-04-28
Aikawa Yoshiyuki
Chairman and CEO
Sell465K @ $3.02$1.41M
2026-04-21
Aikawa Yoshiyuki
Chairman and CEO
Sell3.10M @ $3.02$9.37M
2026-03-06
Aikawa Yoshiyuki
Chairman and CEO
Sell4.42M @ $2.12$9.38M
2024-09-30
SAYAMA MIKE K
Director
Acquired (J)15.0K
2024-09-19
ZUU Co. Ltd.
10% owner
Sell6.20K @ $7.34$45.5K
2024-09-17
ZUU Co. Ltd.
10% owner
Acquired (J)1.50M
2024-09-17
Aikawa Yoshiyuki
Director, Chairman and CEO
Disposed (J)1.50M
2024-08-22
ZUU Co. Ltd.
10% owner
Buy8.40K @ $10.51$88.3K
2024-08-21
ZUU Co. Ltd.
10% owner
Sell4.75K @ $11.38$54.1K
2024-08-20
ZUU Co. Ltd.
10% owner
Sell5.00K @ $11.72$58.6K
2024-08-19
ZUU Co. Ltd.
10% owner
Sell70.0K @ $11.45$801K

Earnings history

beat/miss · move
2026-05-14Beat +11.1% est▲ +3.37%8-K ↗
2026-03-27Beat +15.5% est▲ +12.88%8-K ↗
2025-11-14Beat +8.0% est▲ 0.00%8-K ↗
2025-08-13Miss -85.3% est▼ -3.81%8-K ↗
2025-05-15—▲ +33.82%8-K ↗
2025-03-28—▲ +0.30%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score71 vs 67
Revenue growth-15.5% vs 7.5%
Net margin29.4% vs 10.0%
Return on equity20.5% vs 12.0%
P/E6.5 vs 26.2